Our Pipeline

Developing life-changing gene therapies for devastating diseases.

Voyager’s pipeline includes programs with robust target validation and an efficient path to preclinical and clinical proof of concept that may provide meaningful therapeutic benefit to patients: Huntington’s disease (HD), a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, and spinal muscular atrophy (SMA). Our pipeline focuses on advancing innovative gene therapies that leverage our proprietary next-generation AAV capsids (TRACER) and vectorized antibodies.